Insulet Partners with Glooko as its Preferred Data Management Partner for OmniPod Patients and Healthcare Providers

BILLERICA, Mass., Jan. 5, 2016 /PRNewswire/ -- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its OmniPod^® Insulin Management System, today announced it has partnered with Glooko¹, the leader in diabetes management mobile and web applications, to provide U.S. OmniPod patients and healthcare providers a new data management system named "Insulet Provided Glooko". This new system is available today to patients who use the OmniPod System, as well as healthcare professionals who care for these patients.

"A critical component of diabetes management is the ability for patients, as well as their healthcare providers, to see a complete picture of their health," said Patrick Sullivan, President and Chief Executive Officer. "Having the ability to track and analyze information about a patient's insulin data, in combination with blood glucose levels, diet and exercise data, allows patients and their care teams to optimize and improve their healthcare management. We are pleased to partner with Glooko as Insulet's preferred data management partner and are thrilled to offer Glooko's award winning diabetes management platform with our OmniPod System."

About the New Insulet Provided Glooko System:

With the Insulet Provided Glooko system, OmniPod patients are now able to view data from their OmniPod Personal Diabetes Manager (PDM), Continual Glucose Monitoring (CGM), Blood Glucose Meter (BGM) and fitness tracker on mobile devices, Macs or PCs and proactively share their data with family members and healthcare providers. The platform delivers a leading data management and analytics solution alongside Insulet's differentiated and unique tubeless OmniPod System.

This new system enables healthcare professionals to easily download patients' data from multiple devices and review a robust set of print and online reports during patient visits, including access to detailed insights about their patients' care plans. It also provides care teams with the ability to remotely monitor patients between visits and identify patients whose glucose levels are outside of a normal range or that are experiencing other clinical incidents.

The new Insulet Provided Glooko system has been well received by OmniPod patients and the healthcare professionals who care for these patients. Early feedback has been extremely positive, citing:

• The reports are easy to read and fast to download;
• The easy-to-use integrated kiosk streamlines patient flow and allows more time with patients;
• Insulin, BG and CGM data together in one easy-to-use format improves the healthcare providers' ability to manage the health of their patients.

In addition, OmniPod patients now have access to Glooko's Mobile App, available on iPhone and Android platforms, which allows them to view their OmniPod System data on their phone or tablet, together with their glucose (CGM and/or BGM), diet and exercise data. This "on-the-go" access to data provides patients continuous and more robust information to improve their diabetes management experience.  

Insulet and Glooko have worked collaboratively to ensure a seamless experience for U.S. OmniPod users and healthcare providers who would like to use the new platform. OmniPod patients and healthcare providers who are interested in learning more about this system may call OmniPod Customer Care at 1-800-591-3455.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD) is an innovative medical device company dedicated to making the lives of people with diabetes easier. Through its OmniPod Insulin Management System, Insulet seeks to expand the use of insulin pump therapy among people with insulin-dependent diabetes. The OmniPod is a revolutionary and easy-to-use tubeless insulin pump that features just two parts and a fully-automated cannula insertion. Insulet's Delivery Systems business also partners with global pharmaceutical and biotechnology companies to tailor the OmniPod technology platform for the delivery of subcutaneous drugs across multiple therapeutic areas. Insulet's subsidiary, Neighborhood Diabetes, is a leading distributor of diabetes products and supplies, delivered through a high touch customer service model. To read inspiring stories of people with diabetes living their lives to the fullest with OmniPod, visit our customer blog, Suite D: http://suited.myomnipod.com. Founded in 2000, Insulet Corporation is based in Billerica, Massachusetts. For more information, please visit: http://www.myomnipod.com.

Forward-Looking Statement:

This press release may contain forward-looking statements concerning Insulet's expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on its current expectations and beliefs concerning future developments and their potential effects on Insulet. There can be no assurance that future developments affecting Insulet will be those that it has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond its control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, and other risks and uncertainties described in its Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on February 26, 2015 in the section entitled "Risk Factors," and in its other filings from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of its assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Insulet undertakes no obligation to publicly update or revise any forward-looking statements.

Investor Relations and Media Contact:

Deborah R. Gordon
Vice President, Investor Relations and Corporate Communications
(978) 600-7717
[email protected]

¹ Glooko is the Unified Platform for Diabetes Management and provides an FDA-cleared, HIPAA-compliant Web and Mobile application for diabetes patients and clinicians, which aims to improve outcomes and lowers costs. The platform seamlessly unifies data from over 50 leading blood glucose meters, insulin pumps, continuous glucose monitors, activity trackers and biometric devices to deliver insights that improve personal and clinical decision support. Glooko's mobile app enables patients to easily track and proactively manage all aspects of their diabetes care. Glooko's population management web app and APIs offers diabetes-centric analytics and supplies insightful reports, graphs and pattern-triggered notifications to patients, health systems and payers. The Glooko platform also allows customers and third party developers to create branded modules for Glooko users. Learn more at http://www.glooko.com and follow us at Twitter.com/GlookoInc, and Facebook.com/Glooko.

SOURCE Insulet Corporation

Related Links

http://www.insulet.com